Table 5: Viral suppression among persons aged ≥13 years living with HIV, 17 US jurisdictionsa, 2012-2015
| Characteristic |
Viral Suppression |
| 2012 |
2013 |
2014 |
2015 |
Trend in 2012-2015 |
| (N=440,375) |
(N=451,885) |
(N=464,461) |
(N=477,928) |
EAPC |
95% CI |
P-value |
| No. |
(%) |
No. |
(%) |
No. |
(%) |
No. |
(%) |
Lower |
Upper |
| Sex |
|
|
|
|
|
|
|
|
|
|
|
|
| Male |
184,330 |
54.3 |
199,908 |
57.2 |
214,601 |
59.6 |
221,923 |
59.8 |
3.3 |
3.1 |
3.5 |
<.001 |
| Female |
50,921 |
50.5 |
54,913 |
53.6 |
58,458 |
56.0 |
60,886 |
57.1 |
4.2 |
3.8 |
4.6 |
<.001 |
| Race/Ethnicity |
|
|
|
|
|
|
|
|
|
|
|
|
| Black/Afican American |
80,058 |
46.6 |
87,808 |
49.9 |
94,951 |
52.3 |
99,078 |
52.9 |
4.3 |
4 |
4.6 |
<.001 |
| Hispanic/Latino |
58,732 |
53.8 |
63,416 |
56.0 |
68,760 |
58.6 |
71,787 |
59.0 |
3.2 |
2.9 |
3.6 |
<.001 |
| White |
80,078 |
60.9 |
85,921 |
64.1 |
90,356 |
66.4 |
92,223 |
66.4 |
3 |
2.7 |
3.3 |
<.001 |
| Other |
16,383 |
59.3 |
17,676 |
62.3 |
18,992 |
64.8 |
19,721 |
65.7 |
3.5 |
2.8 |
4.2 |
<.001 |
| Age group at diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
| 13-24 |
6,201 |
39.8 |
7,200 |
45.2 |
7,911 |
49.9 |
8,246 |
52.8 |
9.8 |
8.6 |
10.9 |
<.001 |
| 25-34 |
28,504 |
45.8 |
32,115 |
50.1 |
35,666 |
53.3 |
38,058 |
54.5 |
5.9 |
5.4 |
6.4 |
<.001 |
| 35-44 |
56,423 |
51.6 |
57,282 |
54.3 |
58,184 |
56.8 |
57,243 |
57.1 |
3.5 |
3.1 |
3.9 |
<.001 |
| 45-54 |
88,692 |
56.5 |
94,059 |
59.0 |
98,182 |
61.0 |
98,479 |
61.0 |
2.7 |
2.4 |
3 |
<.001 |
| 55+ |
55,431 |
57.7 |
64,165 |
59.9 |
73,116 |
61.8 |
80,783 |
61.8 |
2.3 |
2 |
2.7 |
<.001 |
| Stage at diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
| HIV infection stage 3(AIDS) |
61,281 |
56.1 |
65,045 |
58.4 |
68,374 |
60.4 |
69,991 |
60.6 |
2.7 |
2.3 |
3 |
<.001 |
| Not known to be HIV infection stage 3 |
173,970 |
52.5 |
189,776 |
55.7 |
204,685 |
58.3 |
212,818 |
58.7 |
3.8 |
3.6 |
4 |
<.001 |
| Transmission Categoryc |
|
|
|
|
|
|
|
|
|
|
|
|
| Male-to-male sexual contact |
135,257 |
56.9 |
148,554 |
60.0 |
160,922 |
62.4 |
168,400 |
62.6 |
3.2 |
3 |
3.5 |
<.001 |
| Injection drug use |
31,578 |
44.9 |
32,747 |
47.2 |
33,706 |
49.1 |
33,182 |
48.8 |
2.9 |
2.4 |
3.4 |
<.001 |
| Male-to-male sexual contact and injection drug use |
15,331 |
53.7 |
16,017 |
56.5 |
16,769 |
59.3 |
16,652 |
59.0 |
3.3 |
2.6 |
4.1 |
<.001 |
| Heterosexual contactd
|
52,111 |
51.1 |
56,492 |
54.0 |
60,613 |
56.3 |
63,499 |
57.3 |
3.9 |
3.5 |
4.2 |
<.001 |
| Othere
|
974 |
52.3 |
1,011 |
54.7 |
1,050 |
57.2 |
1,076 |
58.2 |
3.7 |
0.9 |
6.6 |
.009 |
| Total |
235,251 |
53.4 |
254,821 |
56.4 |
273,059 |
58.8 |
282,809 |
59.2 |
3.5 |
3.3 |
3.7 |
<.001 |
Abbreviations: HIV= Human Immunodeficiency Virus, EAPC=Estimated Annual Percent Change.
Note: The denominator for each characteristic for each year are not presented.
aJurisdictions include California, District of Columbia, Hawaii, Iowa, Illinois, Indiana, Louisiana, Maryland, Michigan, Missouri, New Hampshire, New York, North Dakota, South Carolina, Texas, Utah, and West Virginia.
bDefined as a viral load result of <200 copies/mL or, if the quantitative value was missing, a test interpretation value of “undetected”, at the time of the most recent viral load test during the outcome year.
cData statistically adjusted to account for missing transmission categories.
dHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
eIncludes hemophilia, blood transfusion, perinatal exposure and risk factor not reported or not identified.